Considering that tubular atrophy and tubulointerstitial fibrosis have been proven to be reliable features for the prediction of progression to end‐stage kidney disease,[4, 17] our results suggest that MYDGF might be a potential biomarker for CKD and predict the progression of kidney damage. The gene discussed is MYDGF; the disease is Nephropathy.